Company: HROW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022980
Chunk: 77

Company: HARROW, INC.
Filing Date: 2025-08-11
Form: 10-Q
Item: Item 2
Chunk 77
---
,000  
    $23,558,000  
    $13,616,000  
    $9,942,000 
  
    VEVYE 
     18,641,000  
     4,315,000  
     14,326,000  
     40,156,000  
     6,912,000  
     33,244,000 
  
    Other branded products 
     5,212,000  
     11,681,000  
     (6,469,000) 
     6,169,000  
     20,553,000  
     (14,384,000)
  
    Other revenues 
     85,000  
     68,000  
     17,000  
     171,000  
     147,000  
     24,000 
  
    Branded revenue, net 
     42,274,000  
     27,359,000  
     14,915,000  
     70,054,000  
     41,228,000  
     28,826,000 
  
    ImprimisRx revenue, net 
     21,468,000  
     21,580,000  
     (112,000) 
     41,519,000  
     42,298,000  
     (779,000)

    Total revenues, net 
    $63,742,000  
    $48,939,000  
    $14,803,000  
    $111,573,000  
    $83,526,000  
    $28,047,000 

The
increase in revenues between periods was related to an increase in sales of our branded ophthalmology products, primarily due to the
increase of units sold of IHEEZO and VEVYE during the three and six months ended June 30, 2025 compared to the prior year periods.

Cost
of Sales, Gross Profit and Gross Margin

Our
cost of sales includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients,
personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing equipment and tenant improvements depreciation,
the write-off of obsolete inventory, amortization of acquired product NDAs, and other related